Asylia Announces Formation of Distinguished Scientific Advisory Board
July 22, 2021 08:00 ET
|
Asylia Therapeutics
HOUSTON, July 22, 2021 (GLOBE NEWSWIRE) -- Asylia Therapeutics (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune diseases,...
Asylia Therapeutics, Inc. Announces Closing of $14.5 Million Series A Financing
May 25, 2021 08:00 ET
|
Asylia Therapeutics
HOUSTON, May 25, 2021 (GLOBE NEWSWIRE) -- Asylia Therapeutics, Inc. (“Asylia”), a development-stage biotechnology company advancing novel immune modulating therapies for cancer and autoimmune...